Literature DB >> 16601272

Hypertension, kidney, and transgenics: a fresh perspective.

Linda J Mullins1, Matthew A Bailey, John J Mullins.   

Abstract

In this review, we outline the application and contribution of transgenic technology to establishing the genetic basis of blood pressure regulation and its dysfunction. Apart from a small number of examples where high blood pressure is the result of single gene mutation, essential hypertension is the sum of interactions between multiple environmental and genetic factors. Candidate genes can be identified by a variety of means including linkage analysis, quantitative trait locus analysis, association studies, and genome-wide scans. To test the validity of candidate genes, it is valuable to model hypertension in laboratory animals. Animal models generated through selective breeding strategies are often complex, and the underlying mechanism of hypertension is not clear. A complementary strategy has been the use of transgenic technology. Here one gene can be selectively, tissue specifically, or developmentally overexpressed, knocked down, or knocked out. Although resulting phenotypes may still be complicated, the underlying genetic perturbation is a starting point for identifying interactions that lead to hypertension. We recognize that the development and maintenance of hypertension may involve many systems including the vascular, cardiac, and central nervous systems. However, given the central role of the kidney in normal and abnormal blood pressure regulation, we intend to limit our review to models with a broadly renal perspective.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601272     DOI: 10.1152/physrev.00016.2005

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  33 in total

1.  Lack of association of CYP11B2-344C/T polymorphism with essential hypertension: a meta-analysis.

Authors:  Jian-Fei Chen; Jun Jing; Hu Tan; Min-Bao Song; Shi-Yong Yu; Lan Huang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  ENaCs and ASICs as therapeutic targets.

Authors:  Yawar J Qadri; Arun K Rooj; Catherine M Fuller
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

3.  Aldosterone and amiloride alter ENaC abundance in vascular endothelium.

Authors:  Kristina Kusche-Vihrog; Katja Sobczak; Nadine Bangel; Marianne Wilhelmi; Volodymyr Nechyporuk-Zloy; Albrecht Schwab; Hermann Schillers; Hans Oberleithner
Journal:  Pflugers Arch       Date:  2007-09-22       Impact factor: 3.657

4.  Corin, atrial natriuretic peptide and hypertension.

Authors:  Yiqing Zhou; Jingjing Jiang; Yujie Cui; Qingyu Wu
Journal:  Nephrol Dial Transplant       Date:  2009-01-07       Impact factor: 5.992

Review 5.  The role of ENaC in vascular endothelium.

Authors:  Kristina Kusche-Vihrog; Pia Jeggle; Hans Oberleithner
Journal:  Pflugers Arch       Date:  2013-09-18       Impact factor: 3.657

Review 6.  Regulation of transport in the connecting tubule and cortical collecting duct.

Authors:  Alexander Staruschenko
Journal:  Compr Physiol       Date:  2012-04       Impact factor: 9.090

Review 7.  Pressure natriuresis and the renal control of arterial blood pressure.

Authors:  Jessica R Ivy; Matthew A Bailey
Journal:  J Physiol       Date:  2014-08-08       Impact factor: 5.182

8.  Functional implications of the sex differences in transporter abundance along the rat nephron: modeling and analysis.

Authors:  Rui Hu; Alicia A McDonough; Anita T Layton
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-30

9.  PCSK6-mediated corin activation is essential for normal blood pressure.

Authors:  Shenghan Chen; Pengxiu Cao; Ningzheng Dong; Jianhao Peng; Chunyi Zhang; Hao Wang; Tiantian Zhou; Junhua Yang; Yue Zhang; Elizabeth E Martelli; Sathyamangla V Naga Prasad; Rachel E Miller; Anne-Marie Malfait; Yiqing Zhou; Qingyu Wu
Journal:  Nat Med       Date:  2015-08-10       Impact factor: 53.440

10.  Localization of corin and atrial natriuretic peptide expression in human renal segments.

Authors:  Liang Dong; Hao Wang; Ningzheng Dong; Ce Zhang; Boxin Xue; Qingyu Wu
Journal:  Clin Sci (Lond)       Date:  2016-06-24       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.